Feb 15 (Reuters) - Mesoblast Ltd MSB.AX :
* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents
* Results also demonstrated durable improvement in clinical symptoms, physical function, disease activity relative to placebo
* Results showed single intravenous infusion of proprietary allogeneic cell therapy product candidate MPC-300-IV well tolerated Source text for Eikon: ID:nGNXNQFBYa Further company coverage: MSB.AX